Education
About Us
Working with TipRanks
Follow Us
HeartBeam (BEAT)
NASDAQ:BEAT
BEAT Stock Chart & Stats
$0.66
$0.00(0.00%)
At close: 4:00 PM EST
$0.66
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.54 - $3.48
Previous CloseN/A
Volume12.23K
Average Volume (3M)89.04K
Market Cap
$56.61M
Enterprise Value$37.24M
Total Cash (Recent Filing)$1.86M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.72
Next Earnings
Mar 19, 2026EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.15
Shares Outstanding34,311,590
10 Day Avg. Volume76,817
30 Day Avg. Volume89,039
Financial Highlights & Ratios
PEG Ratio-2.27
Price to Book (P/B)37.05
Price to Sales (P/S)0.00
P/FCF Ratio-4.18
Enterprise Value/Market Cap0.66
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-4.66K
Enterprise Value/Ebitda-1.80
Forecast
1Y Price Target
$7.00Price Target Upside960.61% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial PerformanceThe financial model targets a 70%+ margin on recurring revenue, with cash flow break-even targeted when the company achieves 10% penetration in initial regions.
PartnershipsHeartNexus partnership enables a nationwide reader service, allowing HeartBeam to provide a 24/7 cardiology reader service and timely assessments.
Regulatory ApprovalHeartBeam reiterated expectations of a second 510(k) clearance before year-end to be immediately followed with its pilot commercial launch.
Bears Say
FundingCash on hand combined with interim financing alternatives are sufficient to fund operations for the next several weeks, with a more significant funding event likely following the upcoming 510(k) clearance later this year.
Regulatory And Market RisksPotential risks to the company's price target include regulatory setbacks, delays in commercialization, reimbursement headwinds, and unforeseen competitive threats.
HeartBeam News
BEAT FAQ
What was HeartBeam’s price range in the past 12 months?
HeartBeam lowest stock price was $0.54 and its highest was $3.48 in the past 12 months.
What is HeartBeam’s market cap?
HeartBeam’s market cap is $56.61M.
When is HeartBeam’s upcoming earnings report date?
HeartBeam’s upcoming earnings report date is Mar 19, 2026 which is in 113 days.
How were HeartBeam’s earnings last quarter?
HeartBeam released its earnings results on Nov 13, 2025. The company reported -$0.15 earnings per share for the quarter, missing the consensus estimate of -$0.129 by -$0.021.
Is HeartBeam overvalued?
According to Wall Street analysts HeartBeam’s price is currently Undervalued.
Does HeartBeam pay dividends?
HeartBeam does not currently pay dividends.
What is HeartBeam’s EPS estimate?
HeartBeam’s EPS estimate is -0.16.
How many shares outstanding does HeartBeam have?
HeartBeam has 34,311,590 shares outstanding.
What happened to HeartBeam’s price movement after its last earnings report?
HeartBeam reported an EPS of -$0.15 in its last earnings report, missing expectations of -$0.129. Following the earnings report the stock price went down -0.637%.
Which hedge fund is a major shareholder of HeartBeam?
Currently, no hedge funds are holding shares in BEAT
Company Description
HeartBeam
HeartBeam, Inc., a medical technology company, primarily focuses on telemedicine solutions for the detection and monitoring of cardiac disease outside a healthcare facility setting. The company also focuses on providing diagnostic data to physicians with care management of patients with cardiovascular disease. Its telehealth product comprises a credit card sized electrocardiogram machine and a cloud-based diagnostic software system to address the rapidly growing field of remote patient monitoring. The company was incorporated in 2015 and is headquartered in Santa Clara, California.
BEAT Company Deck
BEAT Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress towards FDA clearance and commercial readiness, including strategic partnerships and successful clinical trials. However, the tight cash position and dependence on the FDA clearance present notable challenges.View all BEAT earnings summariesBEAT Stock 12 Month Forecast
Average Price Target
$7.00
▲(960.61% Upside)
Technical Analysis
Ownership Overview
14.86% Insiders
3.88% Mutual Funds
2.16% Other Institutional Investors
76.24% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---